相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy
Badar Hasan et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2022)
De Novo Malignancies After Liver Transplantation: Experience of a High-Volume Center
Kutay Saglam et al.
JOURNAL OF GASTROINTESTINAL CANCER (2022)
Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy
Simon J. Hong et al.
INFLAMMATORY BOWEL DISEASES (2022)
The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
Hui Tang et al.
FRONTIERS IN ONCOLOGY (2021)
Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease
Hilary Dietz et al.
CANCER MANAGEMENT AND RESEARCH (2021)
Beneficial autoimmunity improves cancer prognosis
Laurence Zitvogel et al.
Nature Reviews Clinical Oncology (2021)
Association Between Topical Calcineurin Inhibitor Use and Risk of Cancer, Including Lymphoma, Keratinocyte Carcinoma, and Melanoma A Systematic Review and Meta-analysis
Megan Lam et al.
JAMA DERMATOLOGY (2021)
Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis
Zheyu Zhang et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2021)
Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation
Chris M. Li et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review
Juliya Fisher et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature
Vivek Kumar et al.
ONCOLOGIST (2020)
Association Between Celiac Disease and Cancer
Irene Marafini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Donor-transmitted cancer in kidney transplant recipients: a systematic review
Albino Eccher et al.
JOURNAL OF NEPHROLOGY (2020)
Patients with chronic autoimmune thyroiditis are not at higher risk for developing clinically overt thyroid cancer: a 10-year follow-up study
Mario Rotondi et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Lung Cancer Survival in Patients With Autoimmune Disease
Saya Jacob et al.
JAMA NETWORK OPEN (2020)
Paraneoplastic syndromes in small cell lung cancer
Zaid Soomro et al.
JOURNAL OF THORACIC DISEASE (2020)
IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex
Alexander J. Valvezan et al.
JCI INSIGHT (2020)
Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer
Kenneth L. Kehl et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
Laura C. Kennedy et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story
Rand Naffouje et al.
CANCERS (2019)
Transmission of breast cancer by a single multiorgan donor to 4 transplant recipients
Yvette A. H. Matser et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease A Systematic Review
Noha Abdel-Wahab et al.
ANNALS OF INTERNAL MEDICINE (2018)
Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry
Paul C. Mayor et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites
William F. Anderson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites
William F. Anderson et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
NCCTG N0879 (Alliance): A Randomized Phase 2 Cooperative Group Trial of Carboplatin, Paclitaxel, and Bevacizumab ± Everolimus for Metastatic Melanoma
Robert R. McWilliams et al.
CANCER (2018)
In-vitro evaluation of MPA-loaded electrospun coaxial fiber membranes for local treatment of glioblastoma tumor cells
Daewoo Han et al.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY (2017)
Epidemiology and Risk Factors for Cancer After Lung Transplantation
C. Berastegui et al.
TRANSPLANTATION PROCEEDINGS (2017)
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Tim Wyant et al.
JOURNAL OF CROHNS & COLITIS (2016)
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
Maria I. Carlo et al.
ONCOLOGIST (2016)
Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options
Saad A. Khan et al.
JAMA ONCOLOGY (2016)
A phase II evaluation of temsirolimus in combination with carboplatin and paclitaxel followed by temsirolimus consolidation as first-line therapy in the treatment of stage III-IV clear cell carcinoma of the ovary.
John H. Farley et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update
Christine E. Staatz et al.
ARCHIVES OF TOXICOLOGY (2014)
Paraneoplastic syndromes in rheumatology
Bernhard Manger et al.
NATURE REVIEWS RHEUMATOLOGY (2014)
Use of Azathioprine and the Risk of Cancer in Inflammatory Bowel Disease
Bjorn Pasternak et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2013)
Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014
Kurt G. Pike et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Cancer risk in patients with Hashimoto's thyroiditis: a nationwide cohort study
Y-K Chen et al.
BRITISH JOURNAL OF CANCER (2013)
Adverse events associated with mTOR inhibitors
Nicolas Pallet et al.
EXPERT OPINION ON DRUG SAFETY (2013)
The treatment strategies of autoimmune disease may need a different approach from conventional protocol: A review
S. Chandrashekara
INDIAN JOURNAL OF PHARMACOLOGY (2012)
Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: A cohort study
Mashiko Setshedi et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cancer Transmission From Organ Donors-Unavoidable But Low Risk
Rajeev Desai et al.
TRANSPLANTATION (2012)
Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients
Eric A. Engels et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Discovery and mechanism of ustekinumab A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders
Jacqueline M. Benson et al.
MABS (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Mechanisms of mTOR inhibitor resistance in cancer therapy
Jennifer S. Carew et al.
TARGETED ONCOLOGY (2011)
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
Virginia E. Kwitkowski et al.
ONCOLOGIST (2010)
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
G. R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis
Andrew E. Grulich et al.
LANCET (2007)
Cancer incidence before and after kidney transplantation
Claire M. Vajdic et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Tumour microenvironment - Opinion - Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
CM Overall et al.
NATURE REVIEWS CANCER (2006)
Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil
R Robson et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Haematopoietic malignancies in rheumatoid arthritis:: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
J Askling et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
A Kandiel et al.
GUT (2005)
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
P Geborek et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Tumor necrosis factor, cancer and anticancer therapy
S Mocellin et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Properties of thalidomide and its analogues: Implications for anticancer therapy
SK Teo
AAPS JOURNAL (2005)
Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies
T Mathew et al.
CLINICAL TRANSPLANTATION (2004)
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (Cellcept) in advanced multiple myeloma patients
N Takebe et al.
CLINICAL CANCER RESEARCH (2004)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation
WS Cherikh et al.
TRANSPLANTATION (2003)
Rapamycins - Mechanism of action and cellular resistance
SL Huang et al.
CANCER BIOLOGY & THERAPY (2003)
Anti-Hu antibodies may indicate a positive response to chemotherapy in paraneoplastic syndrome secondary to small cell lung cancer
CA Douglas et al.
PALLIATIVE MEDICINE (2003)
Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy
FL Luan et al.
TRANSPLANTATION (2002)
Thalidomide as an anti-cancer agent
S Kumar et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2002)
Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: Enhanced cell cycle progression promotes recall antigen responsiveness
TL Vanasek et al.
JOURNAL OF IMMUNOLOGY (2001)
Advances in immunology - Autoimmune diseases
A Davidson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al.
NATURE (2001)
Inflammation and cancer: back to Virchow?
F Balkwill et al.
LANCET (2001)
Adverse gastrointestinal effects of mycophenolate mofetil - Aetiology, incidence and management
M Behrend
DRUG SAFETY (2001)
Mycophenolate mofetil and its mechanisms of action
AC Allison et al.
IMMUNOPHARMACOLOGY (2000)
分享论文
